Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV), successfully met its primary endpoint. The positive results from this second pivotal Phase 3 study will form the basis of the company's upcoming regulatory submission to the U.S. Food and Drug Administration (FDA).

Key Details

  • Primary Endpoint Met: At Week 24, 59% of patients receiving the 300 mg weekly dose achieved the combined primary endpoint of virologic response and ALT normalization, compared to 0% in the delayed-treatment arm (p≤0.0001).
  • Regulatory Timeline: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2027.
  • Commercial Outlook: A potential U.S. commercial launch is targeted for the fourth quarter of 2027, pending regulatory approval.
  • Safety Profile: Brelovitug was reported to be well-tolerated, with the most common adverse event being flu-like illness and no new safety signals observed in the study.